Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.

Clarius Group LLC upped its Regeneron stake by 82.1% last quarter, gobbling up 509 extra shares like they were on clearance.

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...